May 12, 2010 (Baystreet.ca) --
said its first-quarter net loss narrowed to $4.19 million or $0.02 per share from $12.34 million or $0.25 per share in the prior-year period. BELLUS Health Inc.
BELLUS Health Inc.
On 6ix: 6ix.com/news/bellus-health-inc
Earlier from Bluenergies
- Annual Meeting of Shareholders - BELLUS Health provides update on corporate and product developments
- BELLUS Health reports results for first quarter ended March 31, 2010
- BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010
- BELLUS Health ends NC-503 diabetes development program following results
- BELLUS Health and Celtic Therapeutics enter agreement for BELLUS' drug candidate KIACTA(TM)
Later from Bluenergies
- Bellus Health reports results for second quarter ended June 30, 2010
- Health Canada grants VIVIMIND¿ a natural health product number
- BELLUS health announces appointment of Martin Tolar, m.d., ph.d. to its board of directors
- BELLUS health and FB health enter agreement for BELLUS' VIVIMIND¿ in Italy
- BELLUS health reports results for third quarter ended September 30, 2010 and announces receipt of US$5 million from partner celtic therapeutics
Follow Bluenergies into a list and get an email when it puts out news.
Follow Bluenergies